A Sluggish Quarter for Drug Discovery Tools? Depends on Whom You Ask | GenomeWeb

Cellular analysis tools for drug discovery sell … but who’s buying?

According to the quarterly financial reports of several publicly traded companies marketing drug-discovery tools, the answer depends on who’s selling.

This year has thus far seen a remarkable amount of activity in the cell-based assay and high-content screening markets, as several publicly traded tool vendors have claimed their stake, either through merger and acquisition activity, licensing agreements, or internal development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.